Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Associate Professor Vlad Damian Vintila

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

3 More presentations in this session

Presentation thumbnail

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

Assistant Professor P. Kalaydzhiev (Sofia, BG)

Abstract Slides Video

Presentation thumbnail

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

Doctor L. Spadafora (Latina, IT)

Abstract Slides Video

Presentation thumbnail

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

Doctor S. Das (Boston, US)

Access the full session

Session thumbnail

SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

SGLT2i treatment at the beginning of real time exposure in a HFrEF population

Congress Presentation

A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

Congress Presentation

Changes in N-terminal pro b-type natriuretic peptide according to SGLT2 inhibitor utilization patterns in patients hospitalized for decompensated heart failure: a prospective cohort study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources